Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been given an average recommendation of “Moderate Buy” by the nineteen research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, thirteen have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $109.25.

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Citizens Jmp decreased their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. HC Wainwright cut their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 16th. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently made changes to their positions in GPCR. Sterling Capital Management LLC purchased a new stake in Structure Therapeutics during the 1st quarter worth $28,000. State of Wyoming purchased a new stake in Structure Therapeutics during the 2nd quarter worth $28,000. EverSource Wealth Advisors LLC increased its stake in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares during the period. CWM LLC increased its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the period. Finally, ANTIPODES PARTNERS Ltd increased its stake in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after buying an additional 1,146 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 4.5%

Shares of GPCR opened at $41.10 on Wednesday. The firm has a market cap of $2.91 billion, a PE ratio of -52.02 and a beta of -1.31. The company’s fifty day moving average is $52.99 and its two-hundred day moving average is $55.94. Structure Therapeutics has a fifty-two week low of $15.80 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). As a group, equities research analysts anticipate that Structure Therapeutics will post -1.36 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.